# US 2016/0256492 A1 · Method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0256492 A1
- Document ID: US20160256492A1
- Status: Published application
- Kind: A1
- Application number: 15/031,169
- Filed: 2014-10-24
- Published: 2016-09-08
- Earliest claimed: 2013-10-24
- Assignees: Ospedale San Raffaele S.R.L.; Fondazione Telethon
- Applicants: Ospedale San Raffaele S.R.L.; Fondazione Telethon
- Inventors: Luigi Naldini; Bernhard Rudolf Gentner; Erika Zonari; Francesco Boccalatte
- Web page: https://patentgrep.com/patent/US20160256492A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61K 48/0091: {Purification or manufacturing processes for gene therapy compositions}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/18: for HIV
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 15/86: Viral vectors
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2510/00: Genetically modified cells
- C12N 2740/15043: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

## Claims

### Claim 1

A method of preparing a therapeutic cell population for clinical use from a starting population of cells comprising haematopoietic stem cells, said method comprising separating a population of cells that substantially do not express CD38 but which express CD34 from the starting population of cells, and transducing the separated cell population with a vector to obtain the therapeutic cell population.

### Claim 2 (depends on 1)

The method of claim 1 wherein the method comprises the steps of:
a. separating CD38-expression cells from a starting population of cells comprising haematopoietic stem cells;
b. separating CD34-expressing cells from the population of cells obtained in step (a) that do not express CD38;
c. transducing the CD34-expressing cell population obtained in step (b) with a vector to obtain the therapeutic cell population.

### Claim 3 (depends on 1)

The method of claim 1 wherein the method comprises the steps of:
a. contacting a starting population of cells comprising haematopoietic stem cells with an agent reactive for CD38;
b. separating the CD38-reactive cells from the CD38-non-reactive cells;
c. contacting the CD38-non-reactive cells obtained in step (b) with an agent reactive for CD34;
d. separating the CD34-reactive cells from the CD34-non-reactive cells wherein the CD34-reactive cells form the transduction cell population;
e. transducing the transduction cell population with a vector to obtain the therapeutic cell population.

### Claim 4 (depends on 1)

The method according to claim 1 wherein the therapeutic cell population has the CD34+CD38− phenotype.

### Claim 5 (depends on 1)

The method of claim 1 wherein the starting population of cells comprising haematopoietic stem cells is obtained from mobilized peripheral blood, bone marrow or umbilical cord blood.

### Claim 6 (depends on 3)

The method of claim 3 wherein the agents reactive for CD38 or CD34 are anti-CD38 or anti-CD34 antibodies, respectively.

### Claim 7 (depends on 6)

The method of claim 6 wherein the anti-CD38 and/or anti-CD34 antibodies are conjugated to magnetic beads or detectable markers.

### Claim 8 (depends on 2)

The method of claim 2 wherein the CD38-expressing cells and/or CD34-expressing cells are separated using magnetic bead-based separation or flow cytometry.

### Claim 9 (depends on 3)

The method of claim 3 wherein the CD38-reactive cells and/or CD34-reactive cells are separated using magnetic bead-based separation or flow cytometry.

### Claim 10 (depends on 1)

The method of claim 1 wherein the vector is a viral vector.

### Claim 11 (depends on 10)

The method of claim 10 wherein the viral vector is a lentiviral vector.

### Claim 12 (depends on 10)

The method of claim 10 wherein the viral vector comprises a nucleotide of interest.

### Claim 13 (depends on 1)

The method of claim 1 wherein the step of transducing a population of cells with a vector comprises culturing the cells for less than about 44 h.

### Claim 14 (depends on 2)

The method of claim 2, wherein the separated CD38-expressing cells or portion thereof are retained to form a support cell population.

### Claim 15 (depends on 3)

The method of claim 3 wherein the separated CD38-reactive cells or portion thereof are retained to form a support cell population.

### Claim 16 (depends on 14)

The method of claim 14 wherein the support cell population has the CD34+CD38int1, CD34+CD38int2, and/or CD34+CD38+ phenotype.

### Claim 17 (depends on 1)

A therapeutic cell population prepared according to the method of claim 1.

### Claim 18 (depends on 14)

A support cell population prepared according to the method of claim 14.

### Claim 19 (depends on 17)

A pharmaceutical composition comprising the therapeutic cell population of claim 17.

### Claim 20 (depends on 18)

A pharmaceutical composition comprising the support cell population of claim 18.

### Claim at position 21

21-27. (canceled)

### Claim 28 (depends on 17)

A kit comprising the therapeutic and support cell populations of claim 17.

### Claim 29 (depends on 17)

A method of treatment comprising administering the therapeutic cell population of claim 17 to a subject in need thereof.

### Claim 30 (depends on 17, 18)

A method of treatment comprising administering the therapeutic cell population of claim 17 and the support cell population of claim 18 to a subject in need thereof.

### Claim 31 (depends on 30)

The method of claim 30 wherein the therapeutic cell population is administered to the subject prior to administration of the support cell population.

### Claim 32 (depends on 30)

The method of claim 30 wherein the therapeutic cell population is administered to the subject contemporaneously with or simultaneously to administration of the support cell population.

### Claim at position 27

33-37. (canceled)

### Claim 38

A method of gene therapy comprising administering a haematopoietic progenitor cell population to a subject in need thereof, wherein the haematopoietic progenitor cell population has been transduced with a nucleotide of interest.

### Claim 39

A method of gene therapy comprising administering a haematopoietic progenitor cell population to a subject in need thereof, wherein said cells have been separated from a population of cells comprising haematopoietic stem and progenitor cells and then transduced with a nucleotide of interest before administration to the subject.

### Claim 40 (depends on 38)

The method of claim 38, wherein the haematopoietic progenitor cell population has the CD34+CD38int phenotype.

### Claim 41 (depends on 38)

The method of claim 38, wherein the haematopoietic progenitor cell population has a CD34+CD38int1, CD34+CD38int2, and/or CD34+CD38+ phenotype.

### Claim 42 (depends on 38)

The method of claim 38, wherein the transduced progenitor cell population is administered in combination with a population of haematopoietic stem cells.

### Claim 43

A method of controlling the duration of transgene expression in a patient, wherein the duration of transgene expression is controlled by selectively administering transduced haematopoietic stem and/or progenitor cells based on CD38 expression level.

### Claim 44 (depends on 43)

The method of claim 43 wherein increased transgene expression duration is achieved by administering cells with decreased levels of CD38 expression.

### Claim 45

A method for increasing gene transfer efficiency comprising transducing haematopoietic stem or progenitor cells with a vector in the presence of a prostaglandin E2 or a prostaglandin E2 derivative.

### Claim 46 (depends on 45)

The method of claim 45 wherein the prostaglandin E2 derivative is 16,16-dimethyl prostaglandin E2.

### Claim 47 (depends on 1, 45)

The method of claim 45 wherein the transduction of haematopoietic stem cells is carried out as part of the method of claim 1.

### Claim 48 (depends on 39)

The method of claim 39, wherein the haematopoietic progenitor cell population has the CD34+CD38int phenotype.

### Claim 49 (depends on 39)

The method of claim 39, wherein the haematopoietic progenitor cell population has a CD34+CD38int1, CD34+CD38int2, and/or CD34+CD38+ phenotype.

### Claim 50 (depends on 39)

The method of claim 39, wherein the transduced progenitor cell population is administered in combination with a population of haematopoietic stem cells.
